ALTASCIENCES
30.5.2022 18:49:04 CEST | Business Wire | Press release
Altasciences announced today that it has been awarded a 2022 CRO Leadership Award in five categories, marking the seventh year the CRO/CDMO has been deemed a top performer by Clinical Leader and Life Science Leader.
Each year, Clinical Leader and Life Science Leader team up with ISR Reports to determine award recipients by assessing 50 CROs on more than 20 performance metrics in ISR’s annual Quality Benchmarking survey. This year, Altasciences received awards in the following categories: Capabilities, Compatibility, Expertise, Quality, and Reliability.
“Selecting the right CRO can make or break your project,” says Ed Miseta, Chief Editor for Clinical Leader. “It can lead to a successful regulatory submission and approval or cost you a lot of time and effort on a failed study. That makes CRO selection a stressful decision for any clinical operations manager. We believe our CRO Leadership Awards will help managers with their search process and hopefully help to connect them with the right contract partner. These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for work ethic they exhibit in consistently meeting the needs of their drug development clients.”
Altasciences recognizes the importance of consistently exceeding the standards for excellence set by others in the industry, as well as their own. For more than 10 years, Altasciences has been transforming the traditional outsourcing paradigm, building a one-stop outsourcing solution that simplifies and accelerates the early phase drug development process for our partners. To that end, Altasciences is proud to have exceeded the expectations of small to large pharmaceutical companies, and will use the awards as further motivation to support educated, faster, integrated, and more complete early drug development decisions for their partners.
“To be recognized by the industry is not only an honor but a testament to the expertise of our people and the utmost care they show for both our partners and for those who seek the therapies we help develop,” says Chris Perkin, CEO at Altasciences. “To be acknowledged is a point of pride for our company, yes—but more importantly, it serves as a reminder that the more we build on our Capabilities, Compatibility, Expertise, Quality, and Reliability, the more our solutions can help our clients transform lives around the world.”
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005365/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tula Technology Builds Global Momentum Expanding OEM and Tier 1 Engagements4.2.2026 08:00:00 CET | Press release
Provides 2026 business outlook with multiple start of production (SOP) targets in 2027 Tula Technology, Inc., a leader in propulsion efficiency and developer of Dynamic Motor Drive® (DMD), today provided a business update highlighting further technical progress across China and Europe as the Company advances towards global commercialization. In the fourth quarter of 2025, another Global Tier 1 completed DMD testing, achieving efficiency exceeding expectations. The Company also signed two additional memoranda of understanding, expanding engagement with OEMs and Tier 1 suppliers. In total, Tula is advancing six development programs towards a start of production (SOP) in 2027, with additional programs to follow. In China, Tula has recently signed two additional agreements – one with a Chinese OEM and another with a global Tier 1 supplier. The OEM has already begun dynamometer testing to confirm the DMD benefit, and upon meeting expectations, an over-the-air update adding DMD software into
LINVO AG Sponsors Fight Aids Cup 2026 in Monaco4.2.2026 07:00:00 CET | Press release
Football legends unite with royalty for HIV awareness at Stade Louis II When Leonardo Bonucci, Andriy Shevchenko and Clarence Seedorf lined up alongside Formula 1 star Charles Leclerc on January 24, 2026, it wasn't for a trophy - it was for a cause. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203762724/en/ LINVO AG serves as an Official Sponsor of the Fight Aids Cup Monaco 2026, uniting football legends for the global fight against HIV/AIDS. LINVO AG proudly sponsored Cirque FC at the sixth annual Fight Aids Cup, held at Monaco's iconic Stade Louis II. The charity match raised funds for Fight Aids Monaco, the HIV awareness foundation chaired by H.S.H. Princess Stéphanie. For over two decades, Fight Aids Monaco has worked to break down barriers surrounding HIV/AIDS - funding prevention programmes, supporting research, and providing direct assistance to those living with the disease. The Fight Aids Cup has become the fou
Murata’s Releases Technology Guide to Enhance Power Stability in AI-driven Data Centers4.2.2026 03:00:00 CET | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has launched a new technology guide entitled: ‘Optimizing Power Delivery Networks for AI Servers in Next-Generation Data Centers.’ Available on the company’s website, the guide introduces specific power delivery network optimization solutions for AI servers that enhance power stability and reduce power losses across the data center infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203101664/en/ [Murata Manufacturing Co., Ltd.] Technology guide to enhance power stability in AI-driven data centers The guide addresses the rapid advancement and adoption of AI, a trend driving the continuous rollout of new data centers worldwide. As the industry moves toward higher voltage operations and increased equipment density, the resulting increase in overall power consumption has made stable power delivery a critical business issue for data center operators.
The Global Photonics Community Converges in San Francisco as More Than 23,000 Register for Photonics West 20263.2.2026 22:14:00 CET | Press release
The largest annual optics and photonics event highlighted the industry’s best and brightest during a week full of innovation, networking, and research sharing SPIE, the international society for optics and photonics, brought the global optics and photonics community to San Francisco, California, for another successful and enlivening Photonics West. With more than 23,000 registrants, the annual conference and exhibition connected attendees from 40 countries, showcasing the transnational and collaborative spirit of the interdisciplinary industry. The dynamic event ran from 17 to 22 January, with 4,200 technical presentations across 100 conferences, 4 stages of industry-focused panels and presentations, 49 courses, and approximately 1,600 exhibitors in the five expos: Photonics West, BiOS, Quantum West, AR | VR | MR, plus, in its inaugural year, Vision Tech. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203925940/en/ Attend
Vena To Acquire Acterys, Creating a New Category of Enterprise Performance Management: Orchestrated Planning3.2.2026 17:00:00 CET | Press release
The acquisition unites finance foresight and IT innovation in the first Microsoft-native Orchestrated Planning environment, helping enterprises plan better and achieve more by turning strategy into aligned execution in real time. Vena, the only complete FP&A platform powered by agentic AI and purpose-built to amplify the Microsoft technology ecosystem, today announced it has entered into a definitive agreement to acquire Managility Pty Ltd, operating as Acterys (“Acterys”), the industry’s leading Power BI–based operational planning and app development platform, subject to customary closing conditions and regulatory approval. This acquisition unlocks a category-defining way for enterprises to combine planning, analytics, and application development within the Microsoft tools they already trust to run their business. By combining Vena’s Excel-native financial planning and analysis (FP&A) capabilities with Acterys’ proprietary Power BI write-back engine and unified analytics within Micros
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom